Although some revenues will slip out of 2022 due to the need for further development, POET (OTC:POETF) (TSX:PTK.V) is still confident of revenues coming in as planned in the out years. One of the reasons for this is the opportunity it sees in medtech and wearables. Its competitor Rockley Photonics is getting a high valuation as it is partnered with Apple in wearables, but POET believes it can develop a superior solution based on features built into its optical interposer platform that can be directly applied to spectrometers and sensors and is working to address that market. With the Rockley-Apple precedent, POET is in talks with large wearable and mobile phone manufacturers in China and Korea and is working with a Chinese company already active in the field to design a product. POET has demonstrated an ability to develop products rapidly and at much lower cost to its competitors (nearly $400 million and eight years of development by Rockley and only $50 million and four years for POET) due to the simplicity of design of the POET optical interposer. In fact, the largest wearables company is not Apple but Huamei (Amazfit), a Chinese company. POET expects to have deal announced in the first half of 2022 in this market, and would base a capital raise on funding a team in China to build a spectrometer. Rockley has based its product on expensive Silicon Photonics and LEDs that do not have enough wavelengths and thus data, but POET’s solution would be smaller, less expensive and based on lasers able to penetrate the skin and provide information on many more metrics.

I wonder how Apple missed POET.

https://www.yahoo.com/now/poetf-poet-plans-compete-superior-093900733.html